Quest Diagnostics Incorporated (DGX)

Market Cap	21.73B +19.3%
Revenue (ttm)	11.28B +11.0%
Net Income	1.02B +14.2%
EPS	9.05 +14.4%
Shares Out	110.70M
PE Ratio	21.69
Forward PE	17.95
Dividend	$3.44 (1.75%)
Ex-Dividend Date	Apr 6, 2026

Volume	1,038,852
Open	199.99
Previous Close	199.53
Day's Range	194.46 - 200.07
52-Week Range	164.65 - 213.50
Beta	0.65
Analysts	Buy
Price Target	214.38 (+9.23%)
Earnings Date	Apr 21, 2026

About DGX

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceu...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Dec 17, 1996
• Employees: 57,000
• Stock Exchange: NYSE
• Ticker Symbol: DGX
• Website: https://www.questdiagnostics.com

Financial Performance

In 2025, Quest Diagnostics's revenue was $11.04 billion, an increase of 11.78% compared to the previous year's $9.87 billion. Earnings were $988.00 million, an increase of 14.09%.

Analyst Summary

According to 13 analysts, the average rating for DGX stock is "Buy." The 12-month stock price target is $214.38, which is an increase of 9.23% from the latest price.

Price Target

$214.38

(9.23% upside)

Analyst Consensus: Buy